PDS Biotechnology Corp CFO Resigns; Interim Finance Officers Named

What Happened

• PDS Biotechnology Corporation (PDSB) filed an 8-K reporting that Lars Boesgaard submitted his resignation as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer on August 13, 2026, effective September 12, 2026, to pursue other professional endeavors. The company states his resignation was not due to any disagreement with the company’s operations, policies or practices.
• The board appointed Janetta Trochimiuk, the company’s Controller, as interim Principal Accounting Officer, and Frank Bedu-Addo, Ph.D., President and CEO, as interim Principal Financial Officer, each effective September 12, 2026.

Key Details

• Resignation submitted: August 13, 2026; effective date: September 12, 2026.
• Interim appointees effective September 12, 2026: Janetta Trochimiuk (interim Principal Accounting Officer) and Frank Bedu-Addo, Ph.D. (interim Principal Financial Officer).
• Trochimiuk joined PDSB as Controller in December 2019, is age 63, a licensed CPA with 25+ years’ experience, and will continue to receive a base salary of $279,519.57/year; she received no equity awards in connection with the interim appointment.
• The company stated there are no family relationships or special arrangements tied to Trochimiuk’s appointment.

Why It Matters

• This is a material management change affecting the company’s finance and accounting leadership. Investors should note the effective date (Sept 12, 2026) and monitor for announcements of a permanent CFO hire.
• The CEO temporarily taking the Principal Financial Officer role and the Controller stepping in as interim accounting officer may raise governance and financial-reporting oversight questions until permanent appointments are made, but the filing notes the resignation was not due to disagreement with management.
• There is no immediate reported change to compensation beyond Trochimiuk’s continuing base salary and equity eligibility, so direct short-term financial impact appears limited based on this filing.